Table 2.
Baseline patient demographics and clinical characteristics
| Variable | Dose-escalation cohorts |
Dose-expansion cohort |
||
|---|---|---|---|---|
| Mogamulizumab + durvalumab (n = 21) |
Mogamulizumab + tremelimumab (n = 19) |
Mogamulizumab + durvalumab (n = 12) |
Mogamulizumab + tremelimumab (n = 12) |
|
| Age (years), median (range) | 63.0 (23–80) | 57.0 (33–76) | 68.0 (29–76) | 64.5 (46–80) |
| ≥65 years, n (%) | 8 (38.1) | 4 (21.1) | 9 (75.0) | 6 (50.0) |
|
| ||||
| Gender, n (%) | ||||
| Male | 10 (47.6) | 11 (57.9) | 6 (50.0) | 7 (58.3) |
| Female | 11 (52.4) | 8 (42.1) | 6 (50.0) | 5 (41.7) |
|
| ||||
| Race, n (%) | ||||
| White | 19 (90.5) | 12 (63.2) | 12 (100.0) | 9 (75.0) |
| Asian | 0 | 3 (15.8) | 0 | 1 (8.3) |
| Black or African American | 2 (9.5) | 2 (10.5) | 0 | 1 (8.3) |
| Not reported | 0 | 2 (10.5) | 0 | 1 (8.3) |
|
| ||||
| ECOG performance status, n (%) | ||||
| 0 | 7 (33.3) | 9 (47.4) | 5 (41.7) | 3 (25.0) |
| 1 | 14 (66.7) | 10 (52.6) | 7 (58.3) | 9 (75.0) |
|
| ||||
| Time from diagnosis (months), median (range) | 43.9 (8.2–403.3) | 42.1 (12.5–230.5) | 25.3 (7.9–59.0) | 20.5 (8.4–50.6) |
|
| ||||
| Primary tumor type, n (%) | ||||
| Pancreatic | 1 (4.8) | 2 (10.5) | 12 (100.0)a | 12 (100.0)a |
| Colorectal | 5 (23.8) | 5 (26.3) | – | – |
| Sarcoma | 5 (23.8) | 0 | – | – |
| Head and neck | 1 (4.8) | 3 (15.8) | – | – |
| Renal cell | 1 (4.8) | 3 (15.8) | – | – |
| Ovarian | 2 (9.5) | 1 (5.3) | – | – |
| Prostate | 1 (4.8) | 1 (5.3) | – | – |
| NSCLC, non-squamous | 1 (4.8) | 1 (5.3) | – | – |
| NSCLC, squamous | 1 (4.8) | 0 | – | – |
| Anal | 0 | 1 (5.3) | – | – |
| Breast | 1 (4.8) | 0 | – | – |
| Other | 2 (9.5) | 2 (10.5) | – | – |
|
| ||||
| No. of prior cancer regimens, n (%) | ||||
| 0 | 1 (4.8) | 0 | 0 | 0 |
| 1 | 1 (4.8) | 3 (15.8) | 0 | 2 (16.7) |
| 2 | 2 (9.5) | 2 (10.5) | 3 (25.0) | 2 (16.7) |
| 3 | 5 (23.8) | 2 (10.5) | 2 (16.7) | 4 (33.3) |
| 4 | 6 (28.6) | 2 (10.5) | 3 (25.0) | 4 (33.3) |
| ≥5 | 6 (28.6) | 10 (52.6) | 4 (33.3) | 0 |
a
Only patients with pancreatic cancer enrolled in dose-expansion cohort. ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer.